| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Ophthalmology | 57 | 2024 | 195 | 15.600 |
Why?
|
| Giant Cell Arteritis | 33 | 2024 | 61 | 15.310 |
Why?
|
| Papilledema | 36 | 2023 | 78 | 11.960 |
Why?
|
| Optic Nerve Diseases | 24 | 2023 | 87 | 10.380 |
Why?
|
| Pseudotumor Cerebri | 24 | 2023 | 57 | 9.550 |
Why?
|
| Vision Disorders | 37 | 2023 | 212 | 8.660 |
Why?
|
| Eye Diseases | 18 | 2024 | 113 | 7.700 |
Why?
|
| Optic Neuritis | 11 | 2023 | 27 | 6.930 |
Why?
|
| Visual Acuity | 42 | 2023 | 803 | 6.870 |
Why?
|
| Ophthalmoplegia | 14 | 2024 | 55 | 5.700 |
Why?
|
| Visual Fields | 23 | 2023 | 133 | 5.480 |
Why?
|
| Hemianopsia | 14 | 2023 | 22 | 5.400 |
Why?
|
| Magnetic Resonance Imaging | 88 | 2024 | 3456 | 5.390 |
Why?
|
| Space Flight | 12 | 2023 | 116 | 5.380 |
Why?
|
| Optic Neuropathy, Ischemic | 16 | 2023 | 46 | 5.290 |
Why?
|
| Intracranial Hypertension | 15 | 2023 | 117 | 5.000 |
Why?
|
| Clinical Competence | 36 | 2021 | 970 | 4.930 |
Why?
|
| Optic Nerve | 17 | 2024 | 117 | 4.770 |
Why?
|
| Internship and Residency | 34 | 2022 | 1152 | 4.320 |
Why?
|
| Meningioma | 8 | 2023 | 110 | 4.300 |
Why?
|
| Humans | 332 | 2024 | 122412 | 4.290 |
Why?
|
| Optic Disk | 10 | 2023 | 44 | 4.150 |
Why?
|
| Education, Medical, Graduate | 27 | 2022 | 506 | 4.110 |
Why?
|
| Temporal Arteries | 20 | 2024 | 41 | 4.100 |
Why?
|
| Neurology | 9 | 2024 | 108 | 3.940 |
Why?
|
| Retinal Diseases | 11 | 2024 | 172 | 3.720 |
Why?
|
| Educational Measurement | 24 | 2014 | 321 | 3.390 |
Why?
|
| Weightlessness | 7 | 2022 | 45 | 3.370 |
Why?
|
| Embolization, Therapeutic | 9 | 2022 | 225 | 3.360 |
Why?
|
| Meningeal Neoplasms | 6 | 2023 | 173 | 3.320 |
Why?
|
| Optic Atrophy | 7 | 2023 | 47 | 3.240 |
Why?
|
| Pituitary Neoplasms | 6 | 2022 | 82 | 3.000 |
Why?
|
| Curriculum | 16 | 2024 | 713 | 2.820 |
Why?
|
| Blindness | 13 | 2023 | 72 | 2.810 |
Why?
|
| Diplopia | 11 | 2021 | 41 | 2.590 |
Why?
|
| Biopsy | 28 | 2024 | 1251 | 2.470 |
Why?
|
| Ophthalmologists | 4 | 2024 | 17 | 2.460 |
Why?
|
| Orbital Diseases | 7 | 2018 | 92 | 2.450 |
Why?
|
| Tomography, Optical Coherence | 21 | 2024 | 511 | 2.430 |
Why?
|
| Intracranial Pressure | 13 | 2023 | 180 | 2.390 |
Why?
|
| Nystagmus, Pathologic | 6 | 2023 | 22 | 2.370 |
Why?
|
| Myasthenia Gravis | 5 | 2023 | 71 | 2.350 |
Why?
|
| Macular Degeneration | 4 | 2024 | 112 | 2.340 |
Why?
|
| Pupil Disorders | 4 | 2021 | 18 | 2.270 |
Why?
|
| Neuromyelitis Optica | 3 | 2023 | 31 | 2.260 |
Why?
|
| Abducens Nerve Diseases | 3 | 2021 | 7 | 2.210 |
Why?
|
| Competency-Based Education | 12 | 2015 | 70 | 2.170 |
Why?
|
| Teaching | 10 | 2019 | 182 | 2.140 |
Why?
|
| Hydrocephalus | 3 | 2023 | 236 | 2.090 |
Why?
|
| Astronauts | 9 | 2022 | 50 | 2.080 |
Why?
|
| Skull Base Neoplasms | 3 | 2021 | 35 | 2.030 |
Why?
|
| Oculomotor Nerve Diseases | 6 | 2021 | 17 | 2.030 |
Why?
|
| Cranial Nerve Diseases | 3 | 2022 | 25 | 2.020 |
Why?
|
| Miller Fisher Syndrome | 3 | 2021 | 3 | 1.950 |
Why?
|
| Lymphoma, B-Cell | 3 | 2021 | 137 | 1.950 |
Why?
|
| Optic Nerve Neoplasms | 4 | 2023 | 19 | 1.930 |
Why?
|
| Optic Atrophy, Hereditary, Leber | 4 | 2022 | 14 | 1.920 |
Why?
|
| Ocular Motility Disorders | 5 | 2023 | 38 | 1.910 |
Why?
|
| Macula Lutea | 4 | 2024 | 45 | 1.890 |
Why?
|
| Students, Medical | 4 | 2021 | 356 | 1.880 |
Why?
|
| Horner Syndrome | 3 | 2021 | 12 | 1.850 |
Why?
|
| Ophthalmologic Surgical Procedures | 9 | 2017 | 88 | 1.800 |
Why?
|
| Meningitis, Cryptococcal | 3 | 2021 | 21 | 1.780 |
Why?
|
| Football | 2 | 2024 | 29 | 1.770 |
Why?
|
| Scotoma | 4 | 2022 | 16 | 1.710 |
Why?
|
| Thymoma | 2 | 2023 | 17 | 1.710 |
Why?
|
| Nervous System Diseases | 4 | 2024 | 371 | 1.680 |
Why?
|
| Visual Field Tests | 11 | 2023 | 48 | 1.670 |
Why?
|
| Thymus Neoplasms | 2 | 2023 | 39 | 1.670 |
Why?
|
| Posterior Leukoencephalopathy Syndrome | 3 | 2021 | 23 | 1.660 |
Why?
|
| Trochlear Nerve Diseases | 3 | 2021 | 4 | 1.660 |
Why?
|
| Thalamus | 4 | 2022 | 83 | 1.640 |
Why?
|
| Pituitary Apoplexy | 2 | 2022 | 2 | 1.640 |
Why?
|
| Diagnosis, Differential | 31 | 2023 | 1874 | 1.630 |
Why?
|
| Education, Medical, Undergraduate | 3 | 2020 | 166 | 1.630 |
Why?
|
| Female | 91 | 2024 | 64939 | 1.620 |
Why?
|
| Adenoma | 4 | 2022 | 134 | 1.610 |
Why?
|
| Fluorescein Angiography | 12 | 2022 | 137 | 1.600 |
Why?
|
| Carotid-Cavernous Sinus Fistula | 3 | 2022 | 9 | 1.600 |
Why?
|
| Headache | 7 | 2021 | 107 | 1.560 |
Why?
|
| Male | 84 | 2024 | 59581 | 1.500 |
Why?
|
| Middle Aged | 61 | 2024 | 25588 | 1.490 |
Why?
|
| Choroid Diseases | 5 | 2017 | 21 | 1.480 |
Why?
|
| Ophthalmic Artery | 3 | 2021 | 24 | 1.470 |
Why?
|
| Exotropia | 3 | 2023 | 14 | 1.450 |
Why?
|
| Brain | 12 | 2022 | 2948 | 1.440 |
Why?
|
| Retinal Artery Occlusion | 6 | 2021 | 17 | 1.420 |
Why?
|
| Carotid Artery Diseases | 2 | 2022 | 147 | 1.420 |
Why?
|
| Accreditation | 9 | 2014 | 83 | 1.390 |
Why?
|
| Adult | 52 | 2024 | 28743 | 1.380 |
Why?
|
| Takayasu Arteritis | 2 | 2022 | 13 | 1.370 |
Why?
|
| Brain Neoplasms | 6 | 2022 | 1222 | 1.340 |
Why?
|
| Aged | 42 | 2024 | 18779 | 1.300 |
Why?
|
| Waldenstrom Macroglobulinemia | 2 | 2021 | 118 | 1.290 |
Why?
|
| Antibodies, Monoclonal, Humanized | 3 | 2021 | 501 | 1.290 |
Why?
|
| Hearing Loss, Sensorineural | 2 | 2022 | 140 | 1.290 |
Why?
|
| Blindness, Cortical | 4 | 2021 | 15 | 1.240 |
Why?
|
| Glucocorticoids | 15 | 2021 | 379 | 1.210 |
Why?
|
| Tomography, X-Ray Computed | 18 | 2023 | 2035 | 1.210 |
Why?
|
| Retinitis | 2 | 2021 | 17 | 1.190 |
Why?
|
| Glaucoma | 3 | 2023 | 89 | 1.160 |
Why?
|
| Typhus, Endemic Flea-Borne | 2 | 2021 | 19 | 1.140 |
Why?
|
| Hyperopia | 3 | 2017 | 83 | 1.130 |
Why?
|
| Basilar Artery | 2 | 2023 | 25 | 1.130 |
Why?
|
| Eye Infections, Bacterial | 5 | 2017 | 90 | 1.120 |
Why?
|
| Optic Chiasm | 3 | 2024 | 15 | 1.120 |
Why?
|
| Autoantibodies | 7 | 2022 | 420 | 1.120 |
Why?
|
| Myelin-Oligodendrocyte Glycoprotein | 3 | 2023 | 29 | 1.110 |
Why?
|
| Vision, Binocular | 3 | 2021 | 44 | 1.100 |
Why?
|
| Telemedicine | 3 | 2024 | 420 | 1.100 |
Why?
|
| Delivery of Health Care | 8 | 2020 | 602 | 1.070 |
Why?
|
| Tuberculosis, Meningeal | 2 | 2023 | 29 | 1.040 |
Why?
|
| Spinal Puncture | 5 | 2021 | 53 | 1.030 |
Why?
|
| Brain Concussion | 2 | 2020 | 225 | 1.010 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 3 | 2021 | 139 | 1.010 |
Why?
|
| Intracranial Aneurysm | 3 | 2021 | 93 | 0.990 |
Why?
|
| Pandemics | 6 | 2023 | 1103 | 0.980 |
Why?
|
| United States | 32 | 2024 | 10475 | 0.980 |
Why?
|
| Alexia, Pure | 2 | 2022 | 3 | 0.980 |
Why?
|
| Strabismus | 4 | 2023 | 47 | 0.970 |
Why?
|
| Meningitis, Aseptic | 2 | 2021 | 14 | 0.970 |
Why?
|
| Syndrome | 7 | 2023 | 1122 | 0.960 |
Why?
|
| Eye Infections, Fungal | 2 | 2016 | 77 | 0.950 |
Why?
|
| Retinal Vessels | 4 | 2022 | 74 | 0.950 |
Why?
|
| Eye | 5 | 2022 | 227 | 0.940 |
Why?
|
| Orbit | 4 | 2021 | 103 | 0.940 |
Why?
|
| Education, Medical | 3 | 2021 | 285 | 0.920 |
Why?
|
| Wernicke Encephalopathy | 2 | 2022 | 4 | 0.910 |
Why?
|
| Cerebral Ventricle Neoplasms | 2 | 2022 | 16 | 0.910 |
Why?
|
| Hallucinations | 2 | 2014 | 26 | 0.910 |
Why?
|
| Rhabdomyolysis | 2 | 2022 | 35 | 0.900 |
Why?
|
| Anemia, Pernicious | 1 | 2023 | 1 | 0.890 |
Why?
|
| Paraneoplastic Syndromes | 2 | 2021 | 16 | 0.890 |
Why?
|
| Obesity Hypoventilation Syndrome | 1 | 2023 | 3 | 0.890 |
Why?
|
| Central Nervous System Vascular Malformations | 2 | 2022 | 19 | 0.880 |
Why?
|
| Aged, 80 and over | 16 | 2023 | 6303 | 0.880 |
Why?
|
| Subclavian Steal Syndrome | 1 | 2023 | 7 | 0.870 |
Why?
|
| Scalp | 2 | 2021 | 56 | 0.870 |
Why?
|
| Multiple Myeloma | 2 | 2024 | 171 | 0.870 |
Why?
|
| Vertebrobasilar Insufficiency | 1 | 2023 | 5 | 0.870 |
Why?
|
| Eye Pain | 4 | 2024 | 10 | 0.860 |
Why?
|
| Infarction, Posterior Cerebral Artery | 1 | 2022 | 1 | 0.850 |
Why?
|
| Aphasia | 1 | 2023 | 14 | 0.850 |
Why?
|
| Antifungal Agents | 2 | 2016 | 293 | 0.850 |
Why?
|
| Collateral Circulation | 1 | 2023 | 45 | 0.850 |
Why?
|
| Esotropia | 3 | 2021 | 11 | 0.850 |
Why?
|
| Sphenoid Sinusitis | 1 | 2022 | 2 | 0.840 |
Why?
|
| SEER Program | 1 | 2023 | 193 | 0.830 |
Why?
|
| Subclavian Artery | 1 | 2023 | 71 | 0.830 |
Why?
|
| Coloboma | 1 | 2023 | 45 | 0.830 |
Why?
|
| Zinc | 1 | 2023 | 128 | 0.830 |
Why?
|
| Air Travel | 1 | 2022 | 1 | 0.820 |
Why?
|
| Lower Body Negative Pressure | 1 | 2022 | 3 | 0.820 |
Why?
|
| Encephalocele | 1 | 2023 | 51 | 0.820 |
Why?
|
| Amaurosis Fugax | 2 | 2022 | 3 | 0.820 |
Why?
|
| Delayed Diagnosis | 2 | 2023 | 121 | 0.820 |
Why?
|
| Eye Movements | 2 | 2021 | 70 | 0.820 |
Why?
|
| Migraine with Aura | 1 | 2022 | 16 | 0.820 |
Why?
|
| Glycogen Storage Disease Type V | 1 | 2022 | 2 | 0.820 |
Why?
|
| Acetazolamide | 6 | 2022 | 30 | 0.810 |
Why?
|
| Agraphia | 1 | 2022 | 1 | 0.810 |
Why?
|
| Cranial Nerve Neoplasms | 1 | 2022 | 8 | 0.810 |
Why?
|
| Orbital Pseudotumor | 2 | 2019 | 11 | 0.810 |
Why?
|
| Papilloma, Choroid Plexus | 1 | 2022 | 1 | 0.810 |
Why?
|
| Postoperative Complications | 6 | 2023 | 2998 | 0.810 |
Why?
|
| Acute Disease | 7 | 2024 | 1092 | 0.810 |
Why?
|
| Hearing Loss, Bilateral | 2 | 2021 | 15 | 0.810 |
Why?
|
| Polyradiculoneuropathy, Chronic Inflammatory Demyelinating | 1 | 2022 | 4 | 0.800 |
Why?
|
| Subarachnoid Hemorrhage | 1 | 2023 | 74 | 0.800 |
Why?
|
| Reflex, Pupillary | 1 | 2022 | 15 | 0.800 |
Why?
|
| Neuroma, Acoustic | 1 | 2022 | 29 | 0.790 |
Why?
|
| Dyslexia | 1 | 2022 | 20 | 0.790 |
Why?
|
| Cerebellar Ataxia | 1 | 2022 | 65 | 0.790 |
Why?
|
| Neurologists | 2 | 2024 | 17 | 0.790 |
Why?
|
| Ventriculoperitoneal Shunt | 1 | 2022 | 48 | 0.780 |
Why?
|
| Enterovirus A, Human | 1 | 2021 | 3 | 0.780 |
Why?
|
| Hand, Foot and Mouth Disease | 1 | 2021 | 3 | 0.780 |
Why?
|
| Hyperaldosteronism | 1 | 2021 | 15 | 0.780 |
Why?
|
| Fistula | 1 | 2022 | 50 | 0.780 |
Why?
|
| Calciphylaxis | 1 | 2021 | 3 | 0.780 |
Why?
|
| Cryopyrin-Associated Periodic Syndromes | 1 | 2021 | 4 | 0.780 |
Why?
|
| Keratoconjunctivitis Sicca | 1 | 2022 | 42 | 0.780 |
Why?
|
| Superior Vena Cava Syndrome | 1 | 2021 | 17 | 0.770 |
Why?
|
| Spinal Cord Neoplasms | 1 | 2022 | 70 | 0.770 |
Why?
|
| Polyarteritis Nodosa | 1 | 2021 | 7 | 0.770 |
Why?
|
| Myelitis | 1 | 2021 | 15 | 0.760 |
Why?
|
| Pupil | 1 | 2022 | 70 | 0.760 |
Why?
|
| Hematoma, Subdural, Chronic | 1 | 2021 | 9 | 0.760 |
Why?
|
| Fovea Centralis | 1 | 2021 | 10 | 0.760 |
Why?
|
| Occipital Lobe | 2 | 2020 | 32 | 0.760 |
Why?
|
| Xerophthalmia | 1 | 2021 | 7 | 0.760 |
Why?
|
| Arthritis, Rheumatoid | 2 | 2022 | 250 | 0.760 |
Why?
|
| Perception | 1 | 2023 | 215 | 0.760 |
Why?
|
| Solanum tuberosum | 1 | 2021 | 15 | 0.750 |
Why?
|
| Autoimmune Diseases | 2 | 2021 | 248 | 0.750 |
Why?
|
| Vasculitis | 1 | 2021 | 49 | 0.750 |
Why?
|
| Subarachnoid Space | 1 | 2021 | 24 | 0.750 |
Why?
|
| Aneurysm, Ruptured | 1 | 2021 | 36 | 0.750 |
Why?
|
| Drug Costs | 1 | 2021 | 61 | 0.750 |
Why?
|
| HELLP Syndrome | 1 | 2021 | 19 | 0.750 |
Why?
|
| Cerebral Infarction | 3 | 2020 | 46 | 0.750 |
Why?
|
| Brain Abscess | 1 | 2021 | 57 | 0.740 |
Why?
|
| Mesencephalon | 1 | 2021 | 42 | 0.740 |
Why?
|
| Neurosyphilis | 1 | 2021 | 14 | 0.740 |
Why?
|
| Herpes Simplex | 1 | 2021 | 58 | 0.740 |
Why?
|
| Geriatrics | 2 | 2017 | 72 | 0.740 |
Why?
|
| Hashimoto Disease | 1 | 2021 | 21 | 0.740 |
Why?
|
| Acetylcholine Release Inhibitors | 1 | 2021 | 19 | 0.740 |
Why?
|
| Chordoma | 1 | 2021 | 17 | 0.740 |
Why?
|
| Guillain-Barre Syndrome | 1 | 2021 | 28 | 0.730 |
Why?
|
| Lacrimal Duct Obstruction | 1 | 2021 | 22 | 0.730 |
Why?
|
| Ependymoma | 1 | 2022 | 134 | 0.730 |
Why?
|
| Meningitis | 1 | 2021 | 99 | 0.730 |
Why?
|
| Botulinum Toxins, Type A | 2 | 2021 | 166 | 0.720 |
Why?
|
| Tolosa-Hunt Syndrome | 2 | 2020 | 4 | 0.720 |
Why?
|
| Arteriovenous Malformations | 1 | 2021 | 47 | 0.720 |
Why?
|
| Hematoma | 2 | 2016 | 93 | 0.720 |
Why?
|
| Cataract Extraction | 6 | 2011 | 210 | 0.710 |
Why?
|
| Neurocysticercosis | 1 | 2020 | 21 | 0.710 |
Why?
|
| Hemangioma, Cavernous, Central Nervous System | 1 | 2020 | 17 | 0.710 |
Why?
|
| Fellowships and Scholarships | 3 | 2022 | 268 | 0.710 |
Why?
|
| Craniotomy | 2 | 2020 | 108 | 0.710 |
Why?
|
| Doxycycline | 2 | 2019 | 117 | 0.710 |
Why?
|
| Posterior Cerebral Artery | 1 | 2020 | 5 | 0.700 |
Why?
|
| Hemangioma, Cavernous | 1 | 2020 | 19 | 0.700 |
Why?
|
| Blood Sedimentation | 7 | 2021 | 28 | 0.690 |
Why?
|
| G(M1) Ganglioside | 2 | 2022 | 8 | 0.690 |
Why?
|
| Brain Infarction | 1 | 2020 | 30 | 0.690 |
Why?
|
| Retinal Detachment | 1 | 2021 | 84 | 0.690 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2023 | 195 | 0.690 |
Why?
|
| Pregnancy Complications | 2 | 2023 | 503 | 0.680 |
Why?
|
| Postoperative Hemorrhage | 1 | 2020 | 87 | 0.680 |
Why?
|
| Quality Assurance, Health Care | 3 | 2009 | 208 | 0.670 |
Why?
|
| School Admission Criteria | 2 | 2011 | 21 | 0.670 |
Why?
|
| Athletic Injuries | 1 | 2020 | 54 | 0.670 |
Why?
|
| Lacrimal Apparatus | 1 | 2021 | 121 | 0.670 |
Why?
|
| Temporal Lobe | 1 | 2020 | 115 | 0.670 |
Why?
|
| Tears | 1 | 2021 | 150 | 0.660 |
Why?
|
| Ataxia | 1 | 2021 | 168 | 0.660 |
Why?
|
| Cerebral Hemorrhage | 1 | 2020 | 141 | 0.650 |
Why?
|
| Leukemia, Myelomonocytic, Chronic | 1 | 2018 | 5 | 0.640 |
Why?
|
| Vision, Ocular | 1 | 2020 | 123 | 0.640 |
Why?
|
| Skin Diseases, Bacterial | 1 | 2019 | 23 | 0.640 |
Why?
|
| Retinal Vasculitis | 1 | 2018 | 8 | 0.640 |
Why?
|
| Immunocompromised Host | 1 | 2021 | 300 | 0.640 |
Why?
|
| Siphonaptera | 1 | 2018 | 6 | 0.630 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2021 | 236 | 0.630 |
Why?
|
| Glioblastoma | 1 | 2022 | 327 | 0.620 |
Why?
|
| Cerebral Angiography | 5 | 2023 | 102 | 0.620 |
Why?
|
| Immunoglobulin kappa-Chains | 1 | 2018 | 31 | 0.620 |
Why?
|
| Immunity, Innate | 1 | 2021 | 375 | 0.620 |
Why?
|
| Malnutrition | 1 | 2021 | 196 | 0.610 |
Why?
|
| Paraproteinemias | 1 | 2018 | 16 | 0.610 |
Why?
|
| Retrospective Studies | 30 | 2024 | 15879 | 0.610 |
Why?
|
| Multiple Sclerosis | 1 | 2021 | 334 | 0.610 |
Why?
|
| Lacrimal Apparatus Diseases | 1 | 2018 | 48 | 0.600 |
Why?
|
| Ethambutol | 1 | 2017 | 8 | 0.600 |
Why?
|
| Insect Bites and Stings | 1 | 2018 | 37 | 0.600 |
Why?
|
| Maxillary Artery | 1 | 2017 | 3 | 0.600 |
Why?
|
| Neuroimaging | 4 | 2022 | 329 | 0.590 |
Why?
|
| Graft Rejection | 1 | 2021 | 580 | 0.590 |
Why?
|
| Carotid Artery, Internal | 3 | 2021 | 66 | 0.580 |
Why?
|
| Optic Tract | 1 | 2017 | 2 | 0.580 |
Why?
|
| Ovarian Neoplasms | 1 | 2021 | 413 | 0.580 |
Why?
|
| Hypertension | 2 | 2023 | 1265 | 0.580 |
Why?
|
| Veins | 1 | 2017 | 106 | 0.560 |
Why?
|
| Arteriovenous Fistula | 1 | 2017 | 56 | 0.560 |
Why?
|
| Betacoronavirus | 1 | 2020 | 289 | 0.550 |
Why?
|
| Granuloma Annulare | 1 | 2016 | 2 | 0.550 |
Why?
|
| Hemifacial Spasm | 1 | 2016 | 17 | 0.550 |
Why?
|
| Lung Transplantation | 1 | 2020 | 316 | 0.550 |
Why?
|
| Tuberculin Test | 1 | 2017 | 132 | 0.550 |
Why?
|
| Kidney Neoplasms | 1 | 2021 | 431 | 0.540 |
Why?
|
| Specialization | 1 | 2017 | 75 | 0.540 |
Why?
|
| Vitreous Hemorrhage | 1 | 2016 | 9 | 0.540 |
Why?
|
| Head and Neck Neoplasms | 1 | 2021 | 468 | 0.540 |
Why?
|
| Aspergillosis | 1 | 2016 | 42 | 0.530 |
Why?
|
| Interferon-gamma Release Tests | 1 | 2017 | 86 | 0.530 |
Why?
|
| Latent Tuberculosis | 1 | 2017 | 83 | 0.530 |
Why?
|
| Uveitis | 1 | 2016 | 35 | 0.530 |
Why?
|
| Anemia | 1 | 2020 | 339 | 0.530 |
Why?
|
| Blepharospasm | 1 | 2016 | 49 | 0.530 |
Why?
|
| Cooperative Behavior | 1 | 2017 | 216 | 0.520 |
Why?
|
| Fundus Oculi | 5 | 2021 | 63 | 0.520 |
Why?
|
| Interprofessional Relations | 1 | 2017 | 142 | 0.520 |
Why?
|
| Health Services Needs and Demand | 1 | 2017 | 170 | 0.520 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2018 | 193 | 0.510 |
Why?
|
| Health Knowledge, Attitudes, Practice | 3 | 2024 | 814 | 0.500 |
Why?
|
| Antigens, Bacterial | 1 | 2017 | 313 | 0.500 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2021 | 1119 | 0.500 |
Why?
|
| Hypotension | 1 | 2017 | 177 | 0.500 |
Why?
|
| Migraine Disorders | 1 | 2016 | 64 | 0.490 |
Why?
|
| Carbonic Anhydrase Inhibitors | 3 | 2022 | 24 | 0.490 |
Why?
|
| Antibodies, Viral | 1 | 2021 | 1138 | 0.490 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 361 | 0.480 |
Why?
|
| Recurrence | 5 | 2021 | 1412 | 0.480 |
Why?
|
| Craniocerebral Trauma | 1 | 2016 | 140 | 0.480 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 378 | 0.480 |
Why?
|
| Parkinson Disease | 1 | 2021 | 663 | 0.480 |
Why?
|
| Afterimage | 1 | 2014 | 1 | 0.480 |
Why?
|
| Antitubercular Agents | 1 | 2017 | 344 | 0.470 |
Why?
|
| Illusions | 1 | 2014 | 8 | 0.470 |
Why?
|
| Nerve Fibers | 4 | 2017 | 70 | 0.470 |
Why?
|
| Cryptococcosis | 1 | 2014 | 42 | 0.470 |
Why?
|
| Heart Transplantation | 1 | 2021 | 854 | 0.470 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2016 | 184 | 0.460 |
Why?
|
| Intraocular Pressure | 6 | 2023 | 144 | 0.460 |
Why?
|
| Gangliosides | 1 | 2014 | 64 | 0.460 |
Why?
|
| Evidence-Based Medicine | 3 | 2010 | 607 | 0.460 |
Why?
|
| Optic Nerve Injuries | 1 | 2014 | 14 | 0.460 |
Why?
|
| Adrenoleukodystrophy | 2 | 2018 | 9 | 0.460 |
Why?
|
| Carotid Artery Injuries | 1 | 2013 | 39 | 0.450 |
Why?
|
| Academic Medical Centers | 3 | 2021 | 297 | 0.450 |
Why?
|
| Steroids | 2 | 2015 | 203 | 0.440 |
Why?
|
| Retinal Ganglion Cells | 4 | 2017 | 107 | 0.440 |
Why?
|
| Combined Modality Therapy | 6 | 2021 | 1233 | 0.440 |
Why?
|
| Periodicals as Topic | 3 | 2006 | 187 | 0.430 |
Why?
|
| Peer Review, Health Care | 2 | 2003 | 17 | 0.430 |
Why?
|
| Sarcoidosis | 1 | 2013 | 63 | 0.430 |
Why?
|
| Expert Testimony | 2 | 2003 | 39 | 0.430 |
Why?
|
| Central Nervous System Diseases | 1 | 2013 | 105 | 0.420 |
Why?
|
| Mycobacterium tuberculosis | 1 | 2017 | 460 | 0.420 |
Why?
|
| Thymectomy | 3 | 2022 | 24 | 0.420 |
Why?
|
| Surveys and Questionnaires | 11 | 2023 | 3611 | 0.410 |
Why?
|
| Disease Management | 1 | 2016 | 513 | 0.410 |
Why?
|
| Cavernous Sinus | 2 | 2021 | 22 | 0.410 |
Why?
|
| Cat-Scratch Disease | 1 | 2012 | 34 | 0.400 |
Why?
|
| Myelin Sheath | 1 | 2013 | 133 | 0.400 |
Why?
|
| Brain Injuries, Traumatic | 1 | 2017 | 366 | 0.400 |
Why?
|
| Prednisone | 5 | 2021 | 273 | 0.400 |
Why?
|
| Retinal Vein Occlusion | 4 | 2017 | 27 | 0.400 |
Why?
|
| Anti-Bacterial Agents | 4 | 2019 | 2391 | 0.400 |
Why?
|
| Paralysis | 2 | 2022 | 36 | 0.400 |
Why?
|
| C-Reactive Protein | 5 | 2021 | 402 | 0.400 |
Why?
|
| Rickettsia typhi | 1 | 2011 | 12 | 0.390 |
Why?
|
| Burkitt Lymphoma | 2 | 2004 | 146 | 0.380 |
Why?
|
| Methylprednisolone | 3 | 2021 | 90 | 0.380 |
Why?
|
| Dilatation | 2 | 2022 | 68 | 0.380 |
Why?
|
| Radiculopathy | 1 | 2011 | 5 | 0.380 |
Why?
|
| Triamcinolone Acetonide | 1 | 2011 | 36 | 0.370 |
Why?
|
| Artificial Intelligence | 2 | 2024 | 228 | 0.370 |
Why?
|
| Pregnancy | 6 | 2023 | 7101 | 0.360 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2016 | 532 | 0.360 |
Why?
|
| Corpus Callosum | 2 | 2022 | 98 | 0.350 |
Why?
|
| Personnel Selection | 1 | 2011 | 62 | 0.350 |
Why?
|
| Follow-Up Studies | 7 | 2021 | 4984 | 0.350 |
Why?
|
| Drug Therapy, Combination | 9 | 2016 | 1146 | 0.340 |
Why?
|
| Nerve Block | 1 | 2011 | 68 | 0.340 |
Why?
|
| Immunoglobulin G | 4 | 2019 | 772 | 0.340 |
Why?
|
| Diagnostic Techniques, Ophthalmological | 3 | 2024 | 98 | 0.340 |
Why?
|
| Benchmarking | 3 | 2015 | 131 | 0.330 |
Why?
|
| Ischemia | 2 | 2017 | 342 | 0.330 |
Why?
|
| Breast Neoplasms | 1 | 2021 | 2480 | 0.320 |
Why?
|
| Societies, Medical | 5 | 2017 | 673 | 0.320 |
Why?
|
| Immunoglobulins, Intravenous | 2 | 2019 | 141 | 0.320 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2011 | 278 | 0.310 |
Why?
|
| Program Evaluation | 6 | 2009 | 438 | 0.310 |
Why?
|
| Lymphoma, AIDS-Related | 2 | 2013 | 37 | 0.310 |
Why?
|
| Risk Factors | 7 | 2023 | 9868 | 0.310 |
Why?
|
| Models, Educational | 1 | 2008 | 67 | 0.300 |
Why?
|
| Specialty Boards | 2 | 2006 | 21 | 0.300 |
Why?
|
| Vision, Low | 1 | 2007 | 14 | 0.300 |
Why?
|
| Genetic Therapy | 2 | 2022 | 707 | 0.300 |
Why?
|
| Evoked Potentials, Visual | 2 | 2017 | 32 | 0.290 |
Why?
|
| Young Adult | 7 | 2023 | 8805 | 0.290 |
Why?
|
| Brain Diseases | 2 | 2014 | 296 | 0.290 |
Why?
|
| Graves Ophthalmopathy | 1 | 2007 | 12 | 0.290 |
Why?
|
| Recovery of Function | 2 | 2021 | 433 | 0.280 |
Why?
|
| Chronic Disease | 2 | 2021 | 1165 | 0.280 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 2 | 2018 | 33 | 0.270 |
Why?
|
| Fructose | 1 | 2007 | 56 | 0.270 |
Why?
|
| Antibodies, Bacterial | 2 | 2011 | 382 | 0.270 |
Why?
|
| Laser Coagulation | 4 | 2016 | 128 | 0.270 |
Why?
|
| Laminectomy | 1 | 2006 | 26 | 0.270 |
Why?
|
| Laboratories | 1 | 2007 | 83 | 0.270 |
Why?
|
| Professional Competence | 1 | 2007 | 96 | 0.270 |
Why?
|
| Prone Position | 1 | 2006 | 32 | 0.270 |
Why?
|
| Compartment Syndromes | 1 | 2006 | 28 | 0.270 |
Why?
|
| Decompression, Surgical | 2 | 2021 | 97 | 0.260 |
Why?
|
| Facial Pain | 1 | 2005 | 7 | 0.260 |
Why?
|
| Time Factors | 4 | 2021 | 6176 | 0.260 |
Why?
|
| Group Processes | 1 | 2006 | 44 | 0.260 |
Why?
|
| Reproducibility of Results | 7 | 2023 | 2793 | 0.260 |
Why?
|
| Education, Medical, Continuing | 2 | 2007 | 140 | 0.260 |
Why?
|
| Optic Disk Drusen | 1 | 2005 | 3 | 0.250 |
Why?
|
| Endovascular Procedures | 1 | 2014 | 712 | 0.250 |
Why?
|
| Career Choice | 1 | 2006 | 142 | 0.250 |
Why?
|
| Furosemide | 2 | 2006 | 36 | 0.250 |
Why?
|
| Phosphodiesterase Inhibitors | 1 | 2005 | 53 | 0.250 |
Why?
|
| Infusions, Intravenous | 3 | 2021 | 539 | 0.250 |
Why?
|
| Treatment Outcome | 6 | 2022 | 12035 | 0.250 |
Why?
|
| Emergencies | 1 | 2006 | 175 | 0.240 |
Why?
|
| Osteoporosis | 1 | 2006 | 114 | 0.240 |
Why?
|
| Retina | 2 | 2021 | 458 | 0.240 |
Why?
|
| Administration, Oral | 2 | 2019 | 669 | 0.240 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 2 | 2018 | 137 | 0.240 |
Why?
|
| Angiography | 2 | 2022 | 214 | 0.240 |
Why?
|
| Echocardiography, Transesophageal | 2 | 2004 | 241 | 0.240 |
Why?
|
| Disease Progression | 2 | 2023 | 1994 | 0.240 |
Why?
|
| Intracranial Embolism | 1 | 2004 | 25 | 0.240 |
Why?
|
| Outpatients | 1 | 2006 | 254 | 0.230 |
Why?
|
| DNA, Mitochondrial | 2 | 2022 | 211 | 0.230 |
Why?
|
| Stents | 3 | 2021 | 864 | 0.230 |
Why?
|
| Diuretics | 2 | 2006 | 158 | 0.230 |
Why?
|
| Antigens, CD | 2 | 2018 | 421 | 0.230 |
Why?
|
| Myotonia | 1 | 2004 | 2 | 0.230 |
Why?
|
| Pregnancy Complications, Cardiovascular | 1 | 2005 | 103 | 0.230 |
Why?
|
| Paranasal Sinus Diseases | 1 | 2004 | 20 | 0.230 |
Why?
|
| Sports Medicine | 1 | 2024 | 26 | 0.230 |
Why?
|
| Oculomotor Nerve | 1 | 2004 | 5 | 0.230 |
Why?
|
| Periosteum | 1 | 2004 | 33 | 0.230 |
Why?
|
| Information Services | 1 | 2004 | 22 | 0.230 |
Why?
|
| Magnetic Resonance Angiography | 2 | 2023 | 169 | 0.230 |
Why?
|
| Spasm | 1 | 2004 | 48 | 0.230 |
Why?
|
| Endophthalmitis | 1 | 2004 | 76 | 0.220 |
Why?
|
| Prevalence | 4 | 2020 | 2369 | 0.220 |
Why?
|
| Lymphocytosis | 1 | 2003 | 14 | 0.220 |
Why?
|
| Arthritis, Infectious | 1 | 2004 | 60 | 0.220 |
Why?
|
| Chlamydophila Infections | 1 | 2003 | 3 | 0.220 |
Why?
|
| Chlamydophila pneumoniae | 1 | 2003 | 11 | 0.220 |
Why?
|
| Streptococcus agalactiae | 1 | 2004 | 105 | 0.220 |
Why?
|
| Advisory Committees | 1 | 2004 | 148 | 0.220 |
Why?
|
| Tertiary Care Centers | 1 | 2024 | 236 | 0.220 |
Why?
|
| Nerve Sheath Neoplasms | 1 | 2003 | 23 | 0.220 |
Why?
|
| Problem-Based Learning | 1 | 2004 | 68 | 0.220 |
Why?
|
| Journalism, Medical | 1 | 2003 | 9 | 0.220 |
Why?
|
| Drug Hypersensitivity | 1 | 2004 | 96 | 0.210 |
Why?
|
| Guidelines as Topic | 4 | 2009 | 194 | 0.210 |
Why?
|
| Ephedra | 1 | 2002 | 2 | 0.210 |
Why?
|
| Cerebral Revascularization | 1 | 2023 | 21 | 0.210 |
Why?
|
| Whipple Disease | 1 | 2002 | 6 | 0.210 |
Why?
|
| Erectile Dysfunction | 1 | 2005 | 170 | 0.210 |
Why?
|
| Actinobacteria | 1 | 2002 | 13 | 0.210 |
Why?
|
| Single-Blind Method | 3 | 2021 | 231 | 0.210 |
Why?
|
| Actinomycetales Infections | 1 | 2002 | 12 | 0.210 |
Why?
|
| Pilot Projects | 2 | 2024 | 1364 | 0.210 |
Why?
|
| Ubiquinone | 1 | 2022 | 24 | 0.210 |
Why?
|
| Diagnostic Imaging | 1 | 2004 | 269 | 0.210 |
Why?
|
| Retinal Hemorrhage | 2 | 2021 | 23 | 0.210 |
Why?
|
| Methotrexate | 4 | 2016 | 341 | 0.210 |
Why?
|
| Pain | 1 | 2005 | 447 | 0.200 |
Why?
|
| Patient Selection | 2 | 2020 | 681 | 0.200 |
Why?
|
| Writing | 1 | 2003 | 57 | 0.200 |
Why?
|
| Visual Pathways | 1 | 2003 | 81 | 0.200 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2022 | 67 | 0.200 |
Why?
|
| Parenteral Nutrition, Total | 1 | 2022 | 117 | 0.200 |
Why?
|
| Radiation Injuries | 1 | 2004 | 142 | 0.200 |
Why?
|
| Facial Nerve | 1 | 2022 | 25 | 0.200 |
Why?
|
| Carotid Arteries | 1 | 2023 | 151 | 0.200 |
Why?
|
| Fourth Ventricle | 1 | 2022 | 10 | 0.200 |
Why?
|
| Hypertension, Malignant | 1 | 2002 | 4 | 0.200 |
Why?
|
| Arteritis | 1 | 2021 | 6 | 0.200 |
Why?
|
| Encephalomyelitis, Acute Disseminated | 1 | 2022 | 11 | 0.200 |
Why?
|
| Gadolinium | 1 | 2022 | 102 | 0.200 |
Why?
|
| Aircraft | 1 | 2002 | 19 | 0.200 |
Why?
|
| Disability Evaluation | 1 | 2003 | 183 | 0.200 |
Why?
|
| Geriatric Assessment | 1 | 2003 | 168 | 0.200 |
Why?
|
| Pituitary ACTH Hypersecretion | 1 | 2021 | 8 | 0.200 |
Why?
|
| Ascorbic Acid | 1 | 2022 | 78 | 0.200 |
Why?
|
| Radiotherapy | 2 | 2018 | 140 | 0.200 |
Why?
|
| Hydroxyethylrutoside | 1 | 2021 | 1 | 0.200 |
Why?
|
| Optic Atrophy, Autosomal Dominant | 1 | 2021 | 8 | 0.200 |
Why?
|
| Feeding and Eating Disorders | 1 | 2022 | 67 | 0.190 |
Why?
|
| Herpesvirus 2, Human | 1 | 2021 | 13 | 0.190 |
Why?
|
| Technology | 1 | 2022 | 65 | 0.190 |
Why?
|
| Carotid Stenosis | 1 | 2023 | 132 | 0.190 |
Why?
|
| Placebos | 1 | 2022 | 235 | 0.190 |
Why?
|
| Streptococcal Infections | 1 | 2004 | 244 | 0.190 |
Why?
|
| Vitamins | 1 | 2022 | 104 | 0.190 |
Why?
|
| Cranial Nerves | 1 | 2021 | 20 | 0.190 |
Why?
|
| Cerebrospinal Fluid Shunts | 1 | 2022 | 79 | 0.190 |
Why?
|
| Meningeal Arteries | 1 | 2021 | 11 | 0.190 |
Why?
|
| Visual Cortex | 1 | 2003 | 109 | 0.190 |
Why?
|
| Mastectomy | 1 | 2021 | 62 | 0.190 |
Why?
|
| Vena Cava, Superior | 1 | 2021 | 55 | 0.190 |
Why?
|
| Thrombosis | 1 | 2006 | 517 | 0.190 |
Why?
|
| Carbon Monoxide | 1 | 2021 | 27 | 0.190 |
Why?
|
| Carotid Artery, Common | 1 | 2021 | 73 | 0.190 |
Why?
|
| Slit Lamp Microscopy | 1 | 2021 | 5 | 0.190 |
Why?
|
| Communicable Disease Control | 1 | 2023 | 141 | 0.190 |
Why?
|
| Seoul | 1 | 2021 | 1 | 0.190 |
Why?
|
| Emergency Treatment | 1 | 2002 | 86 | 0.190 |
Why?
|
| Injections, Intraocular | 1 | 2021 | 10 | 0.190 |
Why?
|
| Cerebrospinal Fluid Pressure | 2 | 2019 | 16 | 0.190 |
Why?
|
| Cranial Fossa, Posterior | 1 | 2021 | 14 | 0.190 |
Why?
|
| Self Report | 1 | 2024 | 492 | 0.190 |
Why?
|
| Immunologic Deficiency Syndromes | 1 | 2023 | 201 | 0.190 |
Why?
|
| Injections, Intradermal | 1 | 2021 | 31 | 0.190 |
Why?
|
| Cough | 1 | 2021 | 87 | 0.190 |
Why?
|
| Internet | 1 | 2004 | 369 | 0.180 |
Why?
|
| Sleep Apnea Syndromes | 1 | 2002 | 74 | 0.180 |
Why?
|
| Disorders of Excessive Somnolence | 1 | 2021 | 32 | 0.180 |
Why?
|
| Sphenoid Sinus | 1 | 2020 | 12 | 0.180 |
Why?
|
| Rare Diseases | 1 | 2022 | 185 | 0.180 |
Why?
|
| Immunosuppressive Agents | 3 | 2021 | 646 | 0.180 |
Why?
|
| Heart Diseases | 2 | 2002 | 479 | 0.180 |
Why?
|
| Remote Consultation | 1 | 2020 | 22 | 0.180 |
Why?
|
| Health Plan Implementation | 1 | 2020 | 42 | 0.180 |
Why?
|
| Neuroendoscopy | 1 | 2020 | 26 | 0.180 |
Why?
|
| Necrosis | 1 | 2021 | 212 | 0.180 |
Why?
|
| Keratomileusis, Laser In Situ | 1 | 2002 | 148 | 0.180 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2021 | 103 | 0.180 |
Why?
|
| Eyelids | 1 | 2021 | 115 | 0.180 |
Why?
|
| Cognition Disorders | 2 | 2011 | 552 | 0.170 |
Why?
|
| Hematocrit | 1 | 2020 | 111 | 0.170 |
Why?
|
| Biomarkers | 2 | 2020 | 2942 | 0.170 |
Why?
|
| Frontal Lobe | 1 | 2020 | 109 | 0.170 |
Why?
|
| Antineoplastic Agents | 2 | 2022 | 1680 | 0.170 |
Why?
|
| Aquaporin 4 | 1 | 2019 | 15 | 0.170 |
Why?
|
| Antioxidants | 1 | 2022 | 338 | 0.170 |
Why?
|
| Aortic Diseases | 1 | 2002 | 197 | 0.170 |
Why?
|
| Brain Edema | 1 | 2020 | 70 | 0.170 |
Why?
|
| Skin Diseases | 1 | 2021 | 122 | 0.170 |
Why?
|
| Keratitis | 1 | 2020 | 116 | 0.160 |
Why?
|
| Attitude of Health Personnel | 3 | 2021 | 635 | 0.160 |
Why?
|
| Incidence | 2 | 2023 | 3008 | 0.160 |
Why?
|
| Secondary Prevention | 1 | 2020 | 208 | 0.160 |
Why?
|
| Cavernous Sinus Thrombosis | 1 | 2018 | 8 | 0.160 |
Why?
|
| Cost-Benefit Analysis | 1 | 2021 | 490 | 0.160 |
Why?
|
| Neoplasm Metastasis | 1 | 2021 | 655 | 0.160 |
Why?
|
| Blood Pressure | 2 | 2021 | 1300 | 0.160 |
Why?
|
| Aspirin | 1 | 2020 | 222 | 0.160 |
Why?
|
| Pre-Eclampsia | 1 | 2021 | 220 | 0.160 |
Why?
|
| Cellulitis | 1 | 2018 | 64 | 0.160 |
Why?
|
| Carrier State | 1 | 2018 | 76 | 0.150 |
Why?
|
| Eye Neoplasms | 1 | 2018 | 51 | 0.150 |
Why?
|
| Positron-Emission Tomography | 2 | 2018 | 285 | 0.150 |
Why?
|
| Cerebrospinal Fluid | 2 | 2016 | 93 | 0.150 |
Why?
|
| Quality of Health Care | 4 | 2006 | 391 | 0.150 |
Why?
|
| Functional Laterality | 2 | 2015 | 178 | 0.150 |
Why?
|
| Dementia | 1 | 2003 | 442 | 0.150 |
Why?
|
| Meningocele | 1 | 2017 | 20 | 0.150 |
Why?
|
| Ciliary Arteries | 1 | 2017 | 1 | 0.150 |
Why?
|
| Polychondritis, Relapsing | 1 | 2017 | 5 | 0.140 |
Why?
|
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2018 | 87 | 0.140 |
Why?
|
| Foundations | 1 | 2017 | 19 | 0.140 |
Why?
|
| Immunophenotyping | 1 | 2018 | 333 | 0.140 |
Why?
|
| Case-Control Studies | 4 | 2020 | 3231 | 0.140 |
Why?
|
| Fasciitis, Necrotizing | 1 | 2017 | 26 | 0.140 |
Why?
|
| Accidents, Traffic | 1 | 2017 | 99 | 0.140 |
Why?
|
| Practice Patterns, Physicians' | 3 | 2013 | 710 | 0.140 |
Why?
|
| Membrane Proteins | 3 | 1994 | 1527 | 0.140 |
Why?
|
| Facial Muscles | 1 | 2016 | 33 | 0.140 |
Why?
|
| Calcium Channels, Q-Type | 1 | 2016 | 8 | 0.140 |
Why?
|
| Calcium Channels, P-Type | 1 | 2016 | 9 | 0.140 |
Why?
|
| Behcet Syndrome | 2 | 2015 | 16 | 0.140 |
Why?
|
| Convergence, Ocular | 1 | 2016 | 2 | 0.140 |
Why?
|
| Alzheimer Disease | 1 | 2004 | 755 | 0.140 |
Why?
|
| Stroke | 1 | 2004 | 956 | 0.130 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2021 | 645 | 0.130 |
Why?
|
| Ultrasonography | 2 | 2024 | 945 | 0.130 |
Why?
|
| Glaucoma, Angle-Closure | 1 | 2016 | 14 | 0.130 |
Why?
|
| Neuroectodermal Tumors, Primitive | 1 | 2016 | 52 | 0.130 |
Why?
|
| Microvascular Decompression Surgery | 1 | 2015 | 5 | 0.130 |
Why?
|
| Pneumocephalus | 1 | 2015 | 5 | 0.130 |
Why?
|
| Membrane Lipids | 2 | 1994 | 33 | 0.130 |
Why?
|
| Trigeminal Neuralgia | 1 | 2015 | 10 | 0.130 |
Why?
|
| Vitreous Body | 2 | 2009 | 105 | 0.130 |
Why?
|
| Iris | 1 | 2016 | 65 | 0.130 |
Why?
|
| Prognosis | 5 | 2019 | 4492 | 0.130 |
Why?
|
| Prospective Studies | 4 | 2021 | 5970 | 0.130 |
Why?
|
| Vasculitis, Leukocytoclastic, Cutaneous | 1 | 2015 | 5 | 0.130 |
Why?
|
| Dermatomyositis | 1 | 2015 | 20 | 0.130 |
Why?
|
| Vasculitis, Central Nervous System | 1 | 2015 | 12 | 0.130 |
Why?
|
| Adenine | 1 | 2016 | 99 | 0.130 |
Why?
|
| Biopsy, Needle | 1 | 2016 | 232 | 0.130 |
Why?
|
| Retinal Vein | 1 | 2015 | 12 | 0.130 |
Why?
|
| Equipment Design | 1 | 2017 | 598 | 0.120 |
Why?
|
| Health Surveys | 2 | 2009 | 233 | 0.120 |
Why?
|
| ROC Curve | 2 | 2018 | 552 | 0.120 |
Why?
|
| Cryptococcus gattii | 1 | 2014 | 2 | 0.120 |
Why?
|
| Spectrometry, Fluorescence | 3 | 1994 | 87 | 0.120 |
Why?
|
| Flucytosine | 1 | 2014 | 17 | 0.120 |
Why?
|
| Cryptococcus neoformans | 1 | 2014 | 20 | 0.120 |
Why?
|
| Neovascularization, Pathologic | 1 | 2016 | 240 | 0.120 |
Why?
|
| Antigens, Fungal | 1 | 2014 | 34 | 0.120 |
Why?
|
| Antibodies, Fungal | 1 | 2014 | 16 | 0.120 |
Why?
|
| Coronary Artery Disease | 1 | 2021 | 743 | 0.120 |
Why?
|
| Global Health | 3 | 2021 | 556 | 0.120 |
Why?
|
| Immunotherapy | 1 | 2019 | 662 | 0.120 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2016 | 178 | 0.120 |
Why?
|
| Piperidines | 1 | 2016 | 196 | 0.120 |
Why?
|
| Depression | 1 | 2003 | 1204 | 0.120 |
Why?
|
| Stem Cell Transplantation | 1 | 2016 | 239 | 0.120 |
Why?
|
| Amphotericin B | 1 | 2014 | 90 | 0.120 |
Why?
|
| Alcohol Withdrawal Seizures | 1 | 2014 | 1 | 0.120 |
Why?
|
| Skin Neoplasms | 1 | 2021 | 801 | 0.120 |
Why?
|
| Mutation | 3 | 2022 | 5786 | 0.120 |
Why?
|
| Diet | 1 | 2021 | 1091 | 0.120 |
Why?
|
| Third Ventricle | 1 | 2014 | 28 | 0.110 |
Why?
|
| Sarcoidosis, Pulmonary | 1 | 2013 | 11 | 0.110 |
Why?
|
| Angiography, Digital Subtraction | 1 | 2013 | 51 | 0.110 |
Why?
|
| Vestibular Diseases | 1 | 2015 | 67 | 0.110 |
Why?
|
| Mediastinal Diseases | 1 | 2013 | 15 | 0.110 |
Why?
|
| Tremor | 1 | 2015 | 129 | 0.110 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 3 | 2011 | 303 | 0.110 |
Why?
|
| Cysts | 1 | 2014 | 99 | 0.110 |
Why?
|
| Pyrazoles | 1 | 2016 | 301 | 0.110 |
Why?
|
| Phospholipids | 1 | 1994 | 107 | 0.110 |
Why?
|
| Granuloma | 1 | 2013 | 69 | 0.110 |
Why?
|
| Oculomotor Muscles | 1 | 2013 | 63 | 0.110 |
Why?
|
| Child | 8 | 2017 | 24108 | 0.110 |
Why?
|
| Herpes Zoster Ophthalmicus | 1 | 2012 | 12 | 0.110 |
Why?
|
| Atrophy | 2 | 2004 | 226 | 0.110 |
Why?
|
| Pyrimidines | 1 | 2016 | 375 | 0.110 |
Why?
|
| Bartonella henselae | 1 | 2012 | 20 | 0.100 |
Why?
|
| International Agencies | 1 | 2012 | 28 | 0.100 |
Why?
|
| Azithromycin | 1 | 2012 | 45 | 0.100 |
Why?
|
| Demography | 2 | 2024 | 237 | 0.100 |
Why?
|
| Computer-Assisted Instruction | 1 | 2012 | 51 | 0.100 |
Why?
|
| Blepharoptosis | 2 | 2004 | 66 | 0.100 |
Why?
|
| Faculty | 1 | 2013 | 100 | 0.100 |
Why?
|
| Staphylococcal Infections | 1 | 2017 | 552 | 0.100 |
Why?
|
| Creutzfeldt-Jakob Syndrome | 1 | 2011 | 6 | 0.100 |
Why?
|
| Alcoholism | 1 | 2014 | 228 | 0.100 |
Why?
|
| Brain Injuries | 1 | 2017 | 760 | 0.100 |
Why?
|
| Quality Improvement | 1 | 2017 | 621 | 0.100 |
Why?
|
| Lymph Nodes | 1 | 2013 | 378 | 0.100 |
Why?
|
| Health Resources | 1 | 2012 | 115 | 0.090 |
Why?
|
| Immunoglobulin M | 1 | 2011 | 210 | 0.090 |
Why?
|
| Arnold-Chiari Malformation | 1 | 2011 | 50 | 0.090 |
Why?
|
| Glomerular Filtration Rate | 1 | 2014 | 481 | 0.090 |
Why?
|
| Phacoemulsification | 2 | 2013 | 236 | 0.090 |
Why?
|
| Erythrocytes | 1 | 2011 | 207 | 0.090 |
Why?
|
| Immunohistochemistry | 1 | 2014 | 1714 | 0.090 |
Why?
|
| Macrophages | 1 | 2014 | 616 | 0.090 |
Why?
|
| Iatrogenic Disease | 1 | 2011 | 130 | 0.090 |
Why?
|
| Neuropsychological Tests | 2 | 2004 | 922 | 0.080 |
Why?
|
| Blood-Brain Barrier | 1 | 2010 | 141 | 0.080 |
Why?
|
| Neurilemmoma | 1 | 2009 | 45 | 0.080 |
Why?
|
| Scleral Buckling | 1 | 2009 | 13 | 0.080 |
Why?
|
| Glioma | 1 | 2014 | 495 | 0.080 |
Why?
|
| Pregnancy Complications, Neoplastic | 1 | 2009 | 62 | 0.080 |
Why?
|
| Clinical Protocols | 1 | 2010 | 237 | 0.080 |
Why?
|
| Orbital Neoplasms | 1 | 2009 | 65 | 0.080 |
Why?
|
| Exophthalmos | 2 | 2006 | 37 | 0.080 |
Why?
|
| Academies and Institutes | 1 | 2009 | 81 | 0.080 |
Why?
|
| Injections | 1 | 2009 | 155 | 0.080 |
Why?
|
| User-Computer Interface | 1 | 2009 | 151 | 0.080 |
Why?
|
| Safety Management | 1 | 2009 | 110 | 0.080 |
Why?
|
| Drug Administration Schedule | 1 | 2010 | 728 | 0.080 |
Why?
|
| Vitrectomy | 1 | 2009 | 107 | 0.080 |
Why?
|
| Intraoperative Complications | 1 | 2009 | 174 | 0.080 |
Why?
|
| Mentors | 1 | 2009 | 144 | 0.080 |
Why?
|
| Medical Errors | 1 | 2009 | 155 | 0.070 |
Why?
|
| Retreatment | 1 | 2007 | 88 | 0.070 |
Why?
|
| Acute Kidney Injury | 1 | 2014 | 606 | 0.070 |
Why?
|
| Arachnoiditis | 1 | 2006 | 1 | 0.070 |
Why?
|
| Circle of Willis | 1 | 2006 | 2 | 0.070 |
Why?
|
| Spinal Stenosis | 1 | 2006 | 9 | 0.070 |
Why?
|
| Granuloma, Foreign-Body | 1 | 2006 | 10 | 0.070 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2008 | 168 | 0.070 |
Why?
|
| International Cooperation | 1 | 2007 | 160 | 0.070 |
Why?
|
| Employment | 1 | 2006 | 67 | 0.070 |
Why?
|
| Dansyl Compounds | 1 | 1986 | 3 | 0.070 |
Why?
|
| Membranes | 1 | 1986 | 23 | 0.070 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2010 | 1678 | 0.070 |
Why?
|
| Retinal Neovascularization | 1 | 2006 | 14 | 0.070 |
Why?
|
| Cyclic Nucleotide Phosphodiesterases, Type 5 | 1 | 2005 | 5 | 0.070 |
Why?
|
| Lumbar Vertebrae | 1 | 2006 | 107 | 0.060 |
Why?
|
| 3',5'-Cyclic-GMP Phosphodiesterases | 1 | 2005 | 38 | 0.060 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2010 | 1025 | 0.060 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2007 | 370 | 0.060 |
Why?
|
| Phosphoric Diester Hydrolases | 1 | 2005 | 63 | 0.060 |
Why?
|
| Laser Therapy | 1 | 2008 | 246 | 0.060 |
Why?
|
| Nerve Compression Syndromes | 1 | 2005 | 20 | 0.060 |
Why?
|
| Occult Blood | 1 | 2005 | 33 | 0.060 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 1 | 2005 | 64 | 0.060 |
Why?
|
| United States Food and Drug Administration | 1 | 2005 | 147 | 0.060 |
Why?
|
| Polymerase Chain Reaction | 2 | 2012 | 1593 | 0.060 |
Why?
|
| Self Disclosure | 1 | 2004 | 24 | 0.060 |
Why?
|
| Axons | 1 | 2007 | 382 | 0.060 |
Why?
|
| Weight Gain | 1 | 2007 | 377 | 0.060 |
Why?
|
| Gastric Bypass | 1 | 2005 | 68 | 0.060 |
Why?
|
| Infant | 4 | 2003 | 12347 | 0.060 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2011 | 711 | 0.060 |
Why?
|
| Tomography, Emission-Computed | 1 | 2004 | 43 | 0.060 |
Why?
|
| Mydriasis | 1 | 2004 | 7 | 0.060 |
Why?
|
| Leucovorin | 1 | 2004 | 50 | 0.060 |
Why?
|
| Vision Tests | 1 | 2004 | 37 | 0.060 |
Why?
|
| Parietal Lobe | 1 | 2004 | 41 | 0.060 |
Why?
|
| Colitis | 1 | 2005 | 156 | 0.060 |
Why?
|
| Cross Reactions | 1 | 2004 | 192 | 0.060 |
Why?
|
| Skull Base | 1 | 2004 | 51 | 0.060 |
Why?
|
| Eyelid Diseases | 1 | 2004 | 67 | 0.050 |
Why?
|
| Blood Cell Count | 1 | 2023 | 69 | 0.050 |
Why?
|
| Conjunctival Diseases | 1 | 2003 | 31 | 0.050 |
Why?
|
| Electrolytes | 1 | 2023 | 51 | 0.050 |
Why?
|
| Protein Binding | 3 | 1994 | 1740 | 0.050 |
Why?
|
| Radiotherapy, Conformal | 1 | 2003 | 55 | 0.050 |
Why?
|
| Vincristine | 1 | 2004 | 208 | 0.050 |
Why?
|
| Endocarditis, Bacterial | 1 | 2004 | 129 | 0.050 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2004 | 138 | 0.050 |
Why?
|
| Obesity, Morbid | 1 | 2005 | 180 | 0.050 |
Why?
|
| RNA, Bacterial | 1 | 2002 | 53 | 0.050 |
Why?
|
| Workload | 1 | 2003 | 146 | 0.050 |
Why?
|
| Anecdotes as Topic | 1 | 2002 | 3 | 0.050 |
Why?
|
| Traction | 1 | 2021 | 9 | 0.050 |
Why?
|
| Crohn Disease | 1 | 2005 | 283 | 0.050 |
Why?
|
| Photography | 1 | 2023 | 91 | 0.050 |
Why?
|
| Staining and Labeling | 1 | 2022 | 186 | 0.050 |
Why?
|
| Altitude | 1 | 2022 | 22 | 0.050 |
Why?
|
| Adenocarcinoma | 1 | 2009 | 1009 | 0.050 |
Why?
|
| Pregnancy Outcome | 1 | 2005 | 592 | 0.050 |
Why?
|
| Positive-Pressure Respiration | 1 | 2002 | 83 | 0.050 |
Why?
|
| Fatal Outcome | 2 | 2013 | 356 | 0.050 |
Why?
|
| Cyclophosphamide | 1 | 2004 | 422 | 0.050 |
Why?
|
| California | 1 | 2002 | 128 | 0.050 |
Why?
|
| Health Services Research | 1 | 2003 | 184 | 0.050 |
Why?
|
| HIV Infections | 1 | 2013 | 1858 | 0.050 |
Why?
|
| Cerebral Arteries | 1 | 2002 | 79 | 0.050 |
Why?
|
| Body Mass Index | 1 | 2007 | 1412 | 0.050 |
Why?
|
| Virulence | 1 | 2021 | 259 | 0.050 |
Why?
|
| Risk Assessment | 1 | 2010 | 3306 | 0.050 |
Why?
|
| Ambulatory Care Facilities | 1 | 2003 | 227 | 0.050 |
Why?
|
| DNA, Bacterial | 1 | 2002 | 481 | 0.050 |
Why?
|
| Activities of Daily Living | 1 | 2003 | 394 | 0.050 |
Why?
|
| DNA Mutational Analysis | 1 | 2002 | 793 | 0.040 |
Why?
|
| Cerebrospinal Fluid Leak | 1 | 2020 | 43 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2003 | 747 | 0.040 |
Why?
|
| Brain Ischemia | 1 | 2002 | 258 | 0.040 |
Why?
|
| Hemorrhage | 1 | 2003 | 457 | 0.040 |
Why?
|
| Prescription Drugs | 1 | 2020 | 52 | 0.040 |
Why?
|
| Dietary Supplements | 1 | 2002 | 456 | 0.040 |
Why?
|
| Rupture, Spontaneous | 1 | 2018 | 48 | 0.040 |
Why?
|
| Child, Preschool | 3 | 2003 | 13837 | 0.040 |
Why?
|
| Sepsis | 1 | 2003 | 478 | 0.040 |
Why?
|
| Practice Guidelines as Topic | 1 | 2005 | 1247 | 0.040 |
Why?
|
| Adolescent | 4 | 2011 | 18971 | 0.040 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2020 | 256 | 0.040 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2020 | 315 | 0.040 |
Why?
|
| Immunomodulation | 1 | 2018 | 81 | 0.040 |
Why?
|
| Pedigree | 1 | 2021 | 1577 | 0.040 |
Why?
|
| Aorta, Thoracic | 1 | 2002 | 517 | 0.040 |
Why?
|
| Quality of Life | 1 | 2007 | 1905 | 0.040 |
Why?
|
| Mass Screening | 1 | 2003 | 779 | 0.040 |
Why?
|
| Animals | 1 | 2018 | 33898 | 0.040 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2004 | 1250 | 0.040 |
Why?
|
| Cross-Sectional Studies | 2 | 2018 | 3305 | 0.030 |
Why?
|
| Obesity | 1 | 2007 | 1949 | 0.030 |
Why?
|
| Blood Vessel Prosthesis Implantation | 1 | 2004 | 784 | 0.030 |
Why?
|
| Comorbidity | 1 | 2021 | 1488 | 0.030 |
Why?
|
| Pulse Therapy, Drug | 1 | 2015 | 7 | 0.030 |
Why?
|
| Antibodies, Antineutrophil Cytoplasmic | 1 | 2015 | 35 | 0.030 |
Why?
|
| Cyclohexanecarboxylic Acids | 1 | 2015 | 18 | 0.030 |
Why?
|
| Olivary Nucleus | 1 | 2015 | 10 | 0.030 |
Why?
|
| Amines | 1 | 2015 | 36 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2018 | 1231 | 0.030 |
Why?
|
| Flow Cytometry | 1 | 2017 | 810 | 0.030 |
Why?
|
| Neurologic Examination | 1 | 2015 | 196 | 0.030 |
Why?
|
| Vertigo | 1 | 2014 | 35 | 0.030 |
Why?
|
| Ca(2+) Mg(2+)-ATPase | 1 | 1994 | 7 | 0.030 |
Why?
|
| Bromine | 1 | 1994 | 5 | 0.030 |
Why?
|
| gamma-Aminobutyric Acid | 1 | 2015 | 166 | 0.030 |
Why?
|
| Lipid Bilayers | 1 | 1994 | 46 | 0.030 |
Why?
|
| Neurosurgical Procedures | 1 | 2016 | 296 | 0.030 |
Why?
|
| Staphylococcus aureus | 1 | 2017 | 457 | 0.030 |
Why?
|
| Intracranial Thrombosis | 1 | 2013 | 12 | 0.030 |
Why?
|
| Cranial Sinuses | 1 | 2013 | 12 | 0.030 |
Why?
|
| Uveitis, Anterior | 1 | 2012 | 5 | 0.030 |
Why?
|
| Encephalitis, Varicella Zoster | 1 | 2012 | 2 | 0.030 |
Why?
|
| Acyclovir | 1 | 2012 | 45 | 0.030 |
Why?
|
| Herpesvirus 3, Human | 1 | 2012 | 26 | 0.030 |
Why?
|
| Anticonvulsants | 1 | 2015 | 372 | 0.020 |
Why?
|
| Periaqueductal Gray | 1 | 2011 | 5 | 0.020 |
Why?
|
| Basal Ganglia | 1 | 2011 | 53 | 0.020 |
Why?
|
| 14-3-3 Proteins | 1 | 2011 | 54 | 0.020 |
Why?
|
| Aerospace Medicine | 1 | 2011 | 37 | 0.020 |
Why?
|
| DNA, Viral | 1 | 2012 | 492 | 0.020 |
Why?
|
| Down Syndrome | 1 | 2013 | 194 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2003 | 8113 | 0.020 |
Why?
|
| tau Proteins | 1 | 2011 | 189 | 0.020 |
Why?
|
| Purpura | 1 | 2008 | 24 | 0.020 |
Why?
|
| Radiosurgery | 1 | 2009 | 108 | 0.020 |
Why?
|
| Physician Executives | 1 | 2008 | 40 | 0.020 |
Why?
|
| Schools, Medical | 1 | 2008 | 112 | 0.020 |
Why?
|
| Diabetes Mellitus | 1 | 2015 | 838 | 0.020 |
Why?
|
| Health Care Surveys | 1 | 2008 | 282 | 0.020 |
Why?
|
| Computer Simulation | 1 | 2009 | 609 | 0.020 |
Why?
|
| Electroencephalography | 1 | 2011 | 860 | 0.020 |
Why?
|
| Logistic Models | 1 | 2011 | 1767 | 0.020 |
Why?
|
| False Positive Reactions | 1 | 2006 | 143 | 0.020 |
Why?
|
| Data Collection | 1 | 2008 | 383 | 0.020 |
Why?
|
| Photochemotherapy | 1 | 2006 | 33 | 0.020 |
Why?
|
| Sigmoidoscopy | 1 | 2005 | 9 | 0.020 |
Why?
|
| Oral Ulcer | 1 | 2005 | 4 | 0.020 |
Why?
|
| Thiamine | 1 | 2005 | 8 | 0.020 |
Why?
|
| Linear Models | 1 | 2007 | 655 | 0.020 |
Why?
|
| Ulcer | 1 | 2005 | 48 | 0.020 |
Why?
|
| Genital Diseases, Female | 1 | 2005 | 32 | 0.020 |
Why?
|
| Health Status | 1 | 2007 | 366 | 0.020 |
Why?
|
| Metronidazole | 1 | 2005 | 155 | 0.020 |
Why?
|
| Biometry | 1 | 1986 | 129 | 0.020 |
Why?
|
| Malingering | 1 | 2004 | 20 | 0.010 |
Why?
|
| Periodontal Abscess | 1 | 2003 | 2 | 0.010 |
Why?
|
| Lung Abscess | 1 | 2003 | 15 | 0.010 |
Why?
|
| Anticoagulants | 1 | 2008 | 583 | 0.010 |
Why?
|
| Diarrhea | 1 | 2005 | 319 | 0.010 |
Why?
|
| Binding Sites | 1 | 1986 | 1298 | 0.010 |
Why?
|
| Remission, Spontaneous | 1 | 2002 | 68 | 0.010 |
Why?
|
| Pyridostigmine Bromide | 1 | 2002 | 13 | 0.010 |
Why?
|
| Age Factors | 1 | 2008 | 2779 | 0.010 |
Why?
|
| Referral and Consultation | 1 | 2005 | 521 | 0.010 |
Why?
|
| Biomarkers, Tumor | 1 | 2009 | 1431 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2006 | 2012 | 0.010 |
Why?
|
| Radiography | 1 | 2003 | 807 | 0.010 |
Why?
|
| Cholinesterase Inhibitors | 1 | 2002 | 90 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 2006 | 2077 | 0.010 |
Why?
|
| Anti-Infective Agents | 1 | 2003 | 266 | 0.010 |
Why?
|